Educational purposes only. Always verify doses with current references (UpToDate, Micromedex, Handbook of Pediatric Anesthesia, etc.) and your clinical preceptor. Dosing may vary by patient condition, institution protocol, and current guidelines.
// Standard hyperbaric spinal (L3-L4 or L4-L5)
Hyperbaric Bupivacaine 0.75%: 10.5–12 mg (1.4–1.6 mL)
Fentanyl: 15–25 mcg
Preservative-free Morphine: 100–200 mcg
// Morphine → 18–24h analgesia; monitor for delayed resp. depression
| Parameter | Setting |
|---|---|
| Solution | 0.0625–0.125% bupivacaine + fentanyl 2 mcg/mL |
| Basal rate | 8–12 mL/hr |
| PCEA bolus | 6–10 mL |
| Lockout | 15–20 min |
| Max 1h limit | ~30–40 mL/hr combined |
| Test dose | 3 mL 1.5% lido + epi 1:200,000 → watch HR ↑ 20bpm (intravascular) or rapid T-rise (intrathecal) |
✅ First Line — Phenylephrine
Infusion: 25–100 mcg/min (titrate to MAP)
Bolus: 50–100 mcg IV PRN
Preferred: maintains uteroplacental perfusion, ↑ SVR
⚠️ Use Ephedrine If Bradycardic (HR <60)
Bolus: 5–10 mg IV
Mixed α/β agonist → ↑HR + ↑SVR; crosses placenta → fetal tachycardia
Inadequate Block:
If Must Repeat:
| Drug | Indication | Dose | Notes |
|---|---|---|---|
| Oxytocin | PPH / uterotonic | 3 U slow IV bolus, then 10-40 U/L infusion | Slow bolus! Rapid → hypotension, tachycardia, ECG changes |
| Methylergonovine | Uterine atony (PPH) | 0.2 mg IM | CI: hypertension, pre-eclampsia; causes severe vasoconstriction |
| Carboprost (Hemabate) | Uterine atony refractory to oxytocin | 250 mcg IM q15-90min, max 8 doses | CI: asthma (bronchospasm risk); causes ↑BP |
| Misoprostol | PPH prevention/treatment | 800-1000 mcg PR or sublingual | Fever common; widely available |
| Tranexamic Acid (TXA) | PPH within 3h of delivery | 1 g IV over 10 min; may repeat 1g in 30 min | Best if given within 3h; reduces mortality |
| Magnesium Sulfate | Eclampsia/pre-eclampsia | Load: 4-6 g IV over 20 min; Maint: 1-2 g/hr | Toxicity: loss of patellar reflexes → respiratory arrest; antidote: Ca gluconate 1g IV |
HELLP = H-EL-LP:
Anesthesia Issues:
Modifications vs. Standard ACLS:
Perimortem C-Section (PMCS):
// Weight estimate (1-10 years)
Weight (kg) = (Age + 4) × 2
// ETT Size (uncuffed, age >2 years)
ETT (mm ID) = (Age / 4) + 4
Cuffed ETT = (Age / 4) + 3.5 ← preferred
// Insertion depth (oral): ID × 3 or Age/2 + 12
// Laryngoscope Blade
Neonates-<2yr: Miller 0 or 1 (straight)
2-8yr: Miller 2 or Mac 2
>8yr: Mac 3
// Maintenance fluids (Holliday-Segar)
0-10 kg: 4 mL/kg/hr
10-20 kg: 40 mL/hr + 2 mL/kg/hr for each kg >10
>20 kg: 60 mL/hr + 1 mL/kg/hr for each kg >20
| Age | HR (bpm) | SBP (mmHg) | RR (/min) | Weight (kg) |
|---|---|---|---|---|
| Neonate (0-30d) | 100-180 | 50-70 | 40-60 | 2-4 |
| Infant (1-12mo) | 100-160 | 70-100 | 30-50 | 4-10 |
| Toddler (1-3yr) | 90-150 | 80-110 | 24-40 | 10-15 |
| Preschool (3-5yr) | 80-140 | 80-110 | 22-34 | 15-20 |
| School-age (6-12yr) | 70-120 | 85-120 | 18-30 | 20-40 |
| Adolescent (12-18yr) | 60-100 | 90-130 | 12-20 | 40-70 |
Min SBP = 70 + (2 × age in years)
| Drug | IV Dose | Notes |
|---|---|---|
| Propofol | 2.5–3.5 mg/kg (infant); 2–2.5 mg/kg (child); 1.5–2 mg/kg (adolescent) | Titrate to effect; slower in sick/hypovolemic; burns on injection → lidocaine 1mg/kg before |
| Ketamine (IV) | 1–2 mg/kg IV over 60s | Maintains airway reflexes; dissociative; ↑secretions → glycopyrrolate 5-10mcg/kg |
| Ketamine (IM) | 4–6 mg/kg IM | When no IV access; onset 3-5 min; great for uncooperative kids |
| Etomidate | 0.3 mg/kg IV | Hemodynamically stable; avoid in sepsis (adrenal suppression); burns on injection |
| Fentanyl | 1–4 mcg/kg IV | Balanced anesthetic adjunct; titrate slowly; chest wall rigidity at high doses |
| Morphine | 0.05–0.1 mg/kg IV | Histamine release; avoid in neonates (resp depression risk) |
| Midazolam | 0.05–0.1 mg/kg IV (max 5mg) | Premedication: 0.5 mg/kg PO 30 min before (max 20mg) |
Dosing:
IV: 2 mg/kg (infant/toddler)
IV: 1-1.5 mg/kg (older child/adult)
IM: 3-4 mg/kg (max 150mg)
⚠️ Contraindications in Peds:
| Substance | Fasting Time | Examples |
|---|---|---|
| Clear liquids | 2 hours | Water, apple juice, Pedialyte, popsicles |
| Breast milk | 4 hours | — |
| Formula / non-human milk | 6 hours | Cow milk, soy formula |
| Solid food / heavy meal | 8 hours | Fatty foods, meat, fried food |
Remove the stimulus (suction, airway manipulation). Call for help.
100% O2, jaw thrust, CPAP 20-30 cmH2O via mask — positive pressure may break partial laryngospasm
Larson's maneuver: firm pressure with middle finger bilateral laryngospasm notch (posterior to mastoid, behind base of ear)
Propofol 0.5–1 mg/kg IV (sub-induction dose) — often breaks spasm
Succinylcholine 1–2 mg/kg IV (or 4 mg/kg IM if no IV). Atropine 0.02 mg/kg with IM dosing to prevent bradycardia.
If complete spasm with no SpO2: intubate with succinylcholine, rigid bronchoscopy if needed
| Feature | Croup (LTB) | Epiglottitis |
|---|---|---|
| Age | 6mo–3yr | 2–7yr (any age post-Hib vaccine era) |
| Onset | Gradual (days) | Rapid (hours) |
| Fever | Low-grade | High (39-40°C) |
| Voice | Barking/seal cough | Muffled "hot potato" voice |
| Drooling | No | YES — hallmark |
| Position | Any | Tripod (leans forward, chin out) |
| X-ray | "Steeple sign" subglottic narrowing | "Thumbprint sign" enlarged epiglottis |
| Treatment | Racemic epi, dexamethasone 0.6mg/kg | Do NOT agitate — OR for controlled intubation, ENT/anesthesia bedside |
| Anesthesia | Nebulized racemic epi can help; awake intubation avoided | Gas induction in OR (sevo), OR intubation by most experienced; trach standby |
Risk Factors:
Prophylaxis:
| Drug | Class | Starting Dose | Range / Pearls |
|---|---|---|---|
| Dopamine | Catecholamine (dose-dependent) | 2–5 mcg/kg/min | <3: "renal" (historically); 5-10: β1 (↑CO, ↑HR); >10: α (vasoconstriction) |
| Dobutamine | β1 agonist / inotrope | 2.5–10 mcg/kg/min | Up to 20; ↑CO, ↓SVR; useful in HF; may ↑HR; can worsen ischemia |
| Milrinone | PDE-3 inhibitor / inodilator | 0.25–0.5 mcg/kg/min | Loading 50 mcg/kg over 10 min (often omitted); ↑inotropy + vasodilation; renally cleared; hypotension common |
| Norepinephrine | α1/β1 agonist / vasopressor | 0.01–0.1 mcg/kg/min | Up to 0.5+; ↑SVR + mild ↑CO; first-line vasopressor in septic shock; vasoplegia after CPB |
| Epinephrine | α/β agonist | 0.01–0.1 mcg/kg/min | ↑HR, ↑CO, ↑SVR at high doses; post-bypass low CO; anaphylaxis |
| Vasopressin | V1 agonist | 0.01–0.04 U/min | Non-catecholamine vasopressor; vasoplegia; arginine vasopressin deficiency post-CPB; does not ↑HR |
| Nitroglycerin | Organic nitrate / vasodilator | 5–200 mcg/min | Venodilator at low doses, arterial at high; coronary vasodilator; used for HTN, ischemia, preload reduction |
| Nitroprusside | Nitric oxide donor / vasodilator | 0.3–8 mcg/kg/min | Arteriolar + venous dilation; very titratable; cyanide toxicity with prolonged high-dose use; wrap in foil (light-sensitive) |
| Phenylephrine | Pure α1 agonist | 0.1–0.5 mcg/kg/min | ↑SVR only; ↓HR (reflex); useful for isolated ↓SVR; avoid in low CO states |
| Insulin (cardiac) | Metabolic support | 0.5–2 U/kg/hr (GIK) | Glucose-insulin-potassium (GIK); used during ischemic protection in some protocols |
▶Pre-Bypass ("Going On Pump")
⏹Post-Bypass ("Coming Off Pump")
Heparin Dosing:
Loading: 300–400 U/kg IV
Target ACT: ≥480s for CPB
// Check ACT 3–5 min after full dose
// Additional 5,000–10,000 U if subtherapeutic
Maintenance: perfusionist manages on bypass
Heparin resistance: consider antithrombin III deficiency (prior heparin exposure). FFP 1-2 units may restore AT-III.
Protamine Reversal:
Dose: 1 mg protamine per 100 U heparin
Rate: Slow! Over 10–15 min
// Rapid administration → anaphylaxis/hypotension
⚠️ Protamine Adverse Reactions:
Causes:
Management:
Mechanism:
Timing Errors:
Late Inflation:
Inflation after dicrotic notch → ↓coronary diastolic augmentation
Early Inflation:
Before dicrotic notch → increases afterload, impedes LV ejection!
Late Deflation:
Balloon inflated into systole → increased afterload, aortic wall injury
Early Deflation:
Before end-diastole → ↓augmentation, ↓afterload reduction
CI <2.0 L/min/m² despite adequate preload and rate. Assess with TEE first.
Hypovolemia (↓preload)
Signs:
↓CVP, ↓PCWP, ↓LV end-diastolic volume (TEE)
Treatment:
Volume: blood products, crystalloid, colloid
LV Failure (systolic)
Signs:
↑PCWP, ↓CO, dilated hypokinetic LV (TEE)
Treatment:
Inotropes: milrinone, dobutamine, epi; consider IABP
RV Failure
Signs:
↑CVP, ↑PA pressures, dilated RV (TEE)
Treatment:
Inhaled NO, milrinone, vasopressin (not epi which ↑PVR); avoid ↑PEEP
Tamponade
Signs:
↑CVP, equalization pressures, RA/RV collapse (TEE)
Treatment:
Emergent pericardiocentesis or surgical decompression
Vasoplegia (↓SVR)
Signs:
↑CO, ↓MAP, ↓SVR
Treatment:
Norepinephrine, vasopressin, methylene blue
Arrhythmia
Signs:
ECG, rate/rhythm issue
Treatment:
Pacing, cardioversion, antiarrhythmics (amiodarone 150 mg IV)
Ischemia / graft failure
Signs:
ST changes, new wall motion abnormality (TEE)
Treatment:
Notify surgeon; may need re-exploration or re-bypass; vasopressors to maintain diastolic
Apfel Simplified Risk Score:
Treatment Ladder:
End of case
Induction
4h before or night before
End of case (black box warning: QTc)
PACU rescue; sedating
PACU rescue; prokinetic
Use different classes for additive effect. TIVA with propofol reduces baseline risk by ~30%.
Activate MH protocol, call MH hotline: 1-800-644-9737 (MHAUS)
Discontinue all volatile agents. Change circuit + CO2 absorber or use disposable circuit. Run oxygen at 10 L/min.
2.5 mg/kg IV bolus, repeat q5 min PRN up to 10 mg/kg total. Target: resolution of rigidity, ↓ETCO2, ↓HR
Cold saline IVF (3 mL/kg ice-cold NS). Cool body surface. Lavage stomach/bladder/rectum if needed. Stop cooling at 38°C.
Calcium chloride 10 mg/kg IV, sodium bicarbonate 1-2 mEq/kg, insulin + glucose, hyperventilate
Amiodarone 150 mg IV. Avoid calcium channel blockers (interact with dantrolene → hyperkalemia/cardiac arrest)
ICU for 24–36h. Continue dantrolene 1 mg/kg IV q6h × 24–48h. Monitor CK, myoglobin, renal function, electrolytes, lactic acid
Signs (CNS then Cardiac):
CNS (early):
Circumoral numbness/tingling, metallic taste, tinnitus, visual disturbance, agitation, slurred speech, seizures
Cardiac (late):
Conduction delays, ST changes, wide-complex bradycardia, VT/VF, PEA, cardiac arrest
High-Risk Agents:
Treatment — Intralipid 20% Protocol (ASRA Guidelines):
Stop LA injection immediately. Call for help.
Airway: 100% O2, intubate if needed. Benzodiazepines for seizures (avoid propofol — contains lipid but contributes to CV depression). Avoid succinylcholine if possible.
Intralipid 20% bolus: 1.5 mL/kg IV over 1 min → then infusion 0.25 mL/kg/min. If unstable: repeat bolus q3-5 min × 2 more. Max 12 mL/kg total.
ACLS: if cardiac arrest, follow standard protocol. Epinephrine reduced doses (<1 mcg/kg). Avoid lidocaine, vasopressin, calcium channel blockers, β-blockers.
Prolonged resuscitation if needed — lipid sink effect takes time. ECMO consideration if refractory.
| Block Depth (TOF) | Dose | Notes |
|---|---|---|
| Shallow (TOF ≥2 twitches / T2) | 2 mg/kg | Routine reversal; use after T2 reappears |
| Moderate (TOF 1–2, ≥1 post-tetanic) | 2 mg/kg | Still effective with ≥1 twitch present |
| Deep (no TOF, 1–2 post-tetanic counts) | 4 mg/kg | Deep reversal; PTC 1-2 |
| Immediate reversal of rocuronium 1.2 mg/kg | 16 mg/kg | Emergency reversal of RSI dose |
Hemodynamic Calculations:
// Cardiac Output
CO = HR × SV (L/min)
CI = CO / BSA (L/min/m²; normal 2.2–4)
// Mean Arterial Pressure
MAP = DBP + (SBP-DBP)/3 or
MAP = (SBP + 2×DBP)/3
// SVR
SVR = (MAP - CVP) × 80 / CO (dynes·s·cm⁻⁵; normal 800-1200)
// PVR
PVR = (mPAP - PCWP) × 80 / CO (normal <250)
Drug Infusion Rate Formulas:
// mcg/kg/min to mL/hr
Rate (mL/hr) =
[dose (mcg/kg/min) × weight (kg) × 60]
÷ concentration (mcg/mL)
// Example: dopamine 5 mcg/kg/min
// 400mg/250mL = 1600 mcg/mL
// 70kg: 5×70×60 / 1600 = 13.1 mL/hr
// Temperature
°C = (°F - 32) × 5/9
°F = (°C × 9/5) + 32
// Weight
kg = lbs / 2.2
Opioid Equianalgesic (oral → IV parenteral):
You're studying hard for clinical rotations. Let CRNA Tracker watch your application deadlines across all 155+ programs so you can focus on learning — not spreadsheets.
⚕️ Educational Reference Only
This reference is intended for educational purposes for CRNA students and healthcare learners. Always verify all doses, protocols, and clinical decisions with current peer-reviewed references, current guidelines (ASA, ACOG, SCA, AHA), and your attending anesthesiologist or clinical preceptor. Drug doses can vary significantly based on patient factors, comorbidities, and institutional protocols. CRNA Tracker assumes no clinical responsibility for use of this information.